Amyloid ␤40 (A␤40) and its derivatives are being developed as probes for the ante-mortem diagnosis of Alzheimer's disease. Putrescine-A␤40 (PUT-A␤40) showed better plaque targeting than the native A␤40, which was not solely explained by the differences in their blood-brain-barrier (BBB) permeabilities. The objective of this study was to elucidate the physiological and biophysical factors influencing the differential targeting of A␤40 and PUT-A␤40. Despite better plaque-targeting ability, 125 I-PUT-A␤40 was more rapidly cleared from the systemic circulation than amyloid ␤40 labeled with 125 I ( 125 I-A␤40) after i.v. administration in mice. The BBB permeability of both compounds was inhibited by circulating peripheral A␤40 levels. 125 I-A␤40 but not 125 I-PUT-A␤40 was actively taken up by the mouse brain slices in vitro. Only fluorescein-A␤40, not fluorescein-PUT-A␤40, was localized in the brain parenchymal cells in vitro. The metabolism of 125 I-A␤40 in the brain slices was twice as great as 125 I-PUT-A␤40. 125 I-A␤40 efflux from the brain slices was saturable and found to be 5 times greater than that of 125 I-PUT-A␤40. Thioflavin-T fibrillogenesis assay demonstrated that PUT-A␤40 has a greater propensity to form insoluble fibrils compared with A␤40, most likely due to the ability of PUT-A␤40 to form ␤ sheet structure more readily than A␤40. These results demonstrate that the inadequate plaque targeting of A␤40 is due to cellular uptake, metabolism, and efflux from the brain parenchyma. Despite better plaque targeting of PUT-A␤40, its propensity to form fibrils may render it less suitable for human use and thus allow increased focus on the development of novel derivatives of A␤ with improved characteristics.
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Amyloid ␤ (A␤) protein is a hydrophobic peptide that is thought to be neurotoxic. A consensus is emerging that A␤ proteins, as soluble monomers or polymers, play a critical role in the neurotoxicity and subsequent development of amyloid plaque formation, which contributes to the pathology of Alzheimer's disease (AD). The extracellular accumulation of A␤ peptides into plaques is one of the pathological hallmarks for the definitive post-mortem diagnosis of AD. A diagnostic imaging technique capable of directly visualizing these amyloid plaques will provide not only a more definitive premortem diagnosis of AD but also a tool for prognostication and evaluation of putative therapies (Poduslo et al., 2002) .
Currently, no method exists to image "individual" amyloid plaques in humans for a definitive and early diagnosis of AD. Radiolabeled molecular probes that bind to ␤-amyloid plaques have recently been demonstrated both in vitro and in animal studies (Skovronsky et al., 2000; Wengenack et al., 2000a; Agdeppa et al., 2001; Bacskai et al., 2001) . The most notable of these probes is the Pittsburgh compound-B, which allowed the researchers to visualize amyloid plaques by bulk tissue enhancement after positron emission tomography imaging for the first time in AD patients (Klunk et al., 2004) . Although scintigraphic imaging of ␤-amyloid plaques is promising, certain difficulties may be envisioned for clinical application. The most obvious is poor spatial resolution. The spatial resolution of clinically available tomographic scintigraphic techniques (positron emission tomography or singlephoton emission computed tomography) is several times poorer than that of standard three-dimensional magnetic resonance imaging (MRI).
The ability of human A␤40 and putrescine-A␤40 (PUT-A␤40) to selectively target amyloid plaques in AD transgenic mouse (APP,PS1) brain has provided an opportunity to use them as molecular probes to image amyloid plaques with MRI.
125 I-A␤40 was reported to have high in vitro binding affinity to the amyloid plaques in human and APP,PS1 mouse brain slices and high in vivo permeability at the bloodbrain barrier (BBB) (Zlokovic et al., 1993; Maness et al., 1994; Poduslo et al., 1997 Poduslo et al., , 1999 Mackic et al., 2002) ; however, the plaque-targeting ability of 125 I-A␤40 after i.v. injection in AD transgenic mice was low (Wengenack et al., 2000a) . PUT-A␤40 was shown to have 2-fold higher BBB permeability than unmodified A␤40 and was able to target and label amyloid plaques in APP,PS1 animals after i.v. administration. When covalently linked to gadolinium diethylenetriaminepentaacetic acid, which provides contrast for MRI imaging, Gd-PUT-A␤40 was able to provide enough contrast to image amyloid plaques in APP,PS1 mice, whereas Gd-A␤40 failed to provide the required contrast (Poduslo et al., 2002) . The differences in the efficacy of these compounds to label plaques ex vivo cannot be completely explained by the differences in their permeability values at the BBB.
Permeability at the BBB, endothelial transcytosis, as well as diffusion within and efflux from the brain parenchyma are important factors that determine the amount of A␤-probe available to target plaques. The proportion of A␤-probe in the extracellular space of the brain parenchyma versus intracellular uptake is another important consideration that will determine the successful targeting of amyloid plaques. Adequate knowledge of the transport kinetics of human A␤ protein and its derivatives at the BBB and in the brain will allow us to design smart molecular probes capable of labeling plaques in Alzheimer's patients as well as provide further information regarding the dynamics of A␤ transport in the progression of AD.
The objective of the current study was to investigate various factors affecting the in vivo uptake of A␤40 and PUT-A␤40 at the BBB, accumulation within and efflux from the brain tissue in vitro, and binding to the amyloid plaques, as a means to explain the better targeting ability of PUT-A␤40 over native A␤40.
Materials and Methods

Synthesis of Human A␤40
A␤40 was synthesized on an ABI 433 peptide synthesizer (Applied Biosystems, Foster City, CA) using 2-(H-benzotriazol-1-yl)1,1,3,3-tetramethyl uranium hexafluorophate activation and the manufacturer's suggested synthesis protocols. The starting resin was ValNovaSyn TGA resin (Calbiochem-Novabiochem, San Diego, CA). The peptides were cleaved from the solid support using 5% crystalline phenol, 5% water, 2.5% triisopropylsilane, and 87.5% trifluoroacetic acid for 2 h at room temperature and were purified by reverse-phase high-performance liquid chromatography using a heated 250-ϫ 21.2-mm C18 Jupiter column (Phenomenex, Torrance, CA). The weights of the peptides were confirmed by electrospray ionization mass spectrometry (Sciex API 165; Applied Biosystems/MDS Sciex, Foster City, CA).
Synthesis of Fluorescein-Labeled A␤40 (F-A␤40)
After the final deprotection of the N-terminal N␣-fluoren-9-ylmethyloxycarbonyl group, the peptide resin was washed with 12% diisopropylethylamine/dichloromethane (DCM). N-Hydroxysuccinimide-fluorescein (0.2 mM; Pierce, Rockford, IL) was dissolved in 6 ml of dimethylformamide and added to the resin saturated with 12% diisopropylethylamine/DCM. The resin slurry was mixed overnight at room temperature, followed by several washes with dimethylformamide and DCM. The success of the fluorescein addition was confirmed by a negative ninhydrin reaction.
Putrescine Modification of A␤40 and F-A␤40
Putrescine modification of synthetic human A␤40 and F-A␤40 was performed by covalent linkage of the polyamine to carboxylic acid groups using carbodiimide at pH of 6.7 as described previously (Poduslo and Curran, 1996a,b) .
Radioiodination of Proteins
Five hundred micrograms of human A␤40 or PUT-A␤40 was labeled with carrier-free Na 125 I, whereas the bovine serum albumin (BSA) (500 g) was labeled with carrier-free Na 131 I using the chloramine-T procedure as described previously (Poduslo et al., 2001 ). Free radioactive iodine was separated from the radiolabeled protein by dialysis against 0.01 M phosphate-buffered saline at pH 7.4 (Sigma-Aldrich Co., St. Louis, MO). Purity of the radiolabeled proteins was determined by trichloroacetic acid (TCA) precipitation. The radiolabeled protein was considered to be acceptable if the precipitable radioactive counts were greater than 95% of the total counts. The specific activity of the proteins thus obtained was determined as 2.0 Ϯ 0.1 Ci/g. No significant difference was observed between the specific activities of 125 I-A␤40 and 125 I-PUT-A␤40.
Animals
Wild-type (WT) mice (B6/SJL strain) were obtained from the Jackson Laboratory (Bar Harbor, ME). The mice were housed in a virusfree barrier facility under a 12-h light/dark cycle, with ad libitum access to food and water. All the experimental procedures were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals using protocols approved by the Mayo Institutional Animal Care and Use Committee.
PUT-A␤40 Pharmacokinetics Studies
Before the beginning of the experiment, the femoral vein and the femoral artery of each mouse were catheterized under general anesthesia (Poduslo et al., 2001 ). An i.v. bolus dose of 125 I-PUT-A␤40 (100 Ci in 100 l) was administered through the femoral vein. Blood samples (20 l) were obtained from the femoral artery at 0.25-, 1-, 3-, 5-, 10-, and 15-min intervals. At the end of the experiment, an i.v. bolus dose of 131 I-BSA (100 Ci in 100 l) was administered to serve as a measure of residual plasma volume (V p ). One minute after the 131 I-BSA injection, the final blood sample was collected, and the animal was sacrificed. The blood samples were diluted to a volume of 100 l using normal saline, centrifuged, and the supernatant was obtained. After TCA precipitation, the supernatant was assayed for 125 I and 131 I radioactivity in a two-channel gamma counter (Cobra II; PerkinElmer Life and Analytical Sciences, Boston, MA). The measured activity was corrected for the background and crossover of 131 I activity into the 125 I channel. At the end of the experiment, the brain of the animal was removed from the cranial cavity, dissected into cortex, caudate putamen, hippocampus, thalamus, brain stem, and cerebellum, and assayed for 125 I and 131 I radioactivity. The effect of A␤40 on the 125 I-PUT-A␤40 uptake at the blood brain barrier was determined by both coadministering and sequential administration of 1 mg of unlabeled A␤40 with 100 Ci of 125 I-PUT-A␤40.
Metabolism of 125 I-PUT-A␤40
The metabolism of 125 I-PUT-A␤40 in the plasma of WT mice was determined by adding 0.1 Ci of 125 I-PUT-A␤40 to 350 l of plasma. A 20-l sample was taken from the mixture at regular intervals up to 60 min, and the amount of intact 125 I-PUT-A␤40 in the sample was determined by TCA precipitation. The metabolism of 125 I-PUT-A␤40 in the presence of brain, liver, kidney, and spleen slices was determined using the organs obtained from WT mice after perfusion with PBS. The organs were weighed, chopped into 1-mm-thick slices using a tissue slicer (Stoelting Co., Wood Dale, IL), and placed in oxygenated (95% O 2 and 5% CO 2 ) KRB until the start of the experiment. The tissue slices were then transferred to 5 ml of KRB containing 0.1 Ci of 125 I-PUT-A␤40 and incubated at 37°C under 5% CO 2 for the entire length of the experiment. Samples (20 l) of the medium were obtained at regular intervals and assayed for the intact protein by TCA precipitation.
Brain Slices
After sacrificing with an overdose of sodium pentobarbital (200 mg/kg i.p.), the animals were decapitated, and the brains were carefully removed from the cranial cavity. Each brain was cut coronally into 1-mm-thick slices containing cortex and hippocampus. The slices were placed in oxygenated (95% O 2 and 5% CO 2 ) KRB until the start of the experiment.
Brain Slice Uptake of 125 I-A␤40 and 125 I-PUT-A␤40
Effect of Time. After the equilibration in KRB, each brain slice was incubated in 1 ml of donor solution containing 125 I-A␤40 (0.8 Ci/ml KRB) at 37°C. The brain slices were sampled at different time points (0, 10, 15, 30, 45 , and 60 min), rinsed with KRB, and assayed for 125 I radioactivity in a two-channel gamma counter (Cobra II; PerkinElmer Life and Analytical Sciences).
Effect of Donor Concentration. After the equilibration, each brain slice was incubated at 37°C in a 1-ml donor solution containing different concentrations of 125 I-A␤40 (0.05-28.4 Ci/ ml KRB). After 15 min, the brain slices were removed from the donor solutions, rinsed with KRB, and assayed for radioactivity using a dual-channel gamma counter.
Effects of Metabolic Inhibitors. After the equilibration, brain slices was preincubated with the metabolic inhibitors ouabain (1 mM) or 2,4-dinitrophenol (2,4-DNP) (1 mM) for 30 min. Each brain slice was then transferred to 1 ml of donor solution (preincubate ϩ 0.6 Ci/1 ml of 125 I-A␤40 or PUT-A␤40) maintained at 37°C. After 15 min, the brain slices were removed, rinsed with KRB, and assayed for radioactivity in a two-channel gamma counter.
Cellular Accumulation of F-A␤40 and F-PUT-A␤40 in the Brain Parenchyma. Each brain slice was incubated in 1 ml of donor solution containing F-A␤40 or F-PUT-A␤40 (40 g/ml KRB) at 37°C. After 15 min, the slice was removed from the donor solution, placed on a coverslip moistened with KRB, and imaged under a Zeiss LSM 410 (Carl Zeiss, Thornwood, NY) laser confocal microscope.
I-A␤40 and I-PUT-A␤40 Efflux from Brain Slices
WT mice brain slices were equilibrated in KRB for 15 min at 37°C. Each slice was then incubated in a 1-ml donor solution containing various concentrations of 125 I-A␤40 or 125 I-PUT-A␤40 at 37°C for 30 min, washed with KRB, and incubated in 5 ml of KRB (receiving medium). The brain slices were harvested at various time points: 0, 10, 15, and 30 min, rinsed with KRB, and assayed for 125 I radioactivity. The initial rates of efflux (Ͻ15 min) of these compounds from the brain slices were calculated at various donor concentrations. The rates of efflux were normalized by the donor concentrations and plotted against log donor concentrations.
A␤40 and PUT-A␤40 Fibril Formation
Thioflavin T (THT) is a fluorescent dye that exhibits substantial enhancement in the fluorescence intensity upon binding to amyloid fibrils. Due to an excellent correlation between the THT fluorescence and the amount of amyloid fibrils, THT fibrillogenesis assay is widely used to quantify the amyloid fibril formation. In the current study, A␤40 and PUT-A␤40 fibril formation kinetics were followed using THT fibrillogenesis assay, which is detailed as follows: A␤40 and PUT-A␤40 were incubated at 37°C in TRIS-EDTA buffer (50 mM Tris, 5 mM EDTA, and 150 mM NaCl) under continuous shaking (200 rpm) for 24 h. A 60-l aliquot of the reaction mixture was obtained at 0, 1, 2, 4, 6, 9, 12, 24, 48, 90 , and 120 h, mixed with 1.2 ml of 5 M THT in TRIS-EDTA and assayed for fluorescence (excitation , 450 nm; emission , 480 nm). The fluorescence intensity of each compound was normalized with the maximal fluorescence value of the compound and plotted against time.
Circular Dichroism Spectroscopy
The secondary structures of A␤40 and PUT-A␤40 were determined using circular dichroism (CD) spectroscopy. A 20 M solution of each protein was prepared in PBS, pH 7.2, filtered using a 0.22-m syringe filter, and transferred to a 0.2-cm path length quartz cuvette. The CD spectra of A␤40 and PUT-A␤40 were obtained from 260 to 200 nm at 4°C, scanning every 1 nm with an averaging time of 5 s, on an AVIV CD spectrometer model 215 (Aviv Instruments, Newington, NH).
Data Analysis
The 125 I-PUT-A␤40 plasma concentration profile after the single i.v. bolus dose of 125 I-A␤40 was best described by a biexponential disposition function C(t) ϭ Ae Ϫ␣t ϩ Be Ϫ␤t , where C(t) ϭ 125 I-PUT-A␤40 per milliliter of plasma, A and B are the intercepts and ␣ and ␤ are the slopes of the biexponential curve. Pharmacokinetic parameters were estimated by nonlinear curve fitting using Gauss-Newton (Levenberg and Hartley) algorithm and iterative reweighting (WinNonlin Professional, version 4.1; Pharsight, Mountain View, CA). Secondary parameters such as the C max (maximum plasma concentration), the first [t 1/2(␣) ] and the second [t 1/2(␤) ] phase half-lives, the plasma clearance (Cl), the steady-state volume of distribution (V ss ), and area under the plasma concentration curve (AUC) were also calculated using WinNonlin. The mean values of controls and treatments were compared by Student's t test using GraphPad Prism version 4.0 (GraphPad Software, San Diego, CA).
Cerebrovascular permeability coefficient-surface area product (PS) and V p measurements were calculated as described previously by Poduslo (1993) . The residual brain region V p (microliters per gram) is calculated as:
where q p is the radioactivity (counts per minute) of 131 I-BSA present in the tissue. C v is the 131 I-BSA concentration (counts per minute per milliliter) in plasma, W is the dry weight (grams) of the brain region, and R is the wet weight/dry weight ratio for mice of a defined age group. From the total 125 I-A␤40 content (q T ) (counts per minute) of the brain region, the amount of 125 I-A␤40 that enters the brain region extravascular space (q) (counts per minute per gram) is calculated as: (3) where t is the circulation time, q(t) is the extravascular 125 I activity in the brain region at time t, and ͐ 0 t C p dt is the plasma concentration time integral of 125 I-A␤40. The initial rates of efflux of 125 I-A␤40 and 125 I-PUT-A␤40 from the WT brain slices were normalized by the donor concentrations and plotted against log donor concentrations (log C). The IC 50 of 125 I-A␤40 efflux from the brain slices in vitro was determined by fitting the following equation to the data using GraphPad Prism version 3.03 (GraphPad Software).
where NE max is the maximum normalized efflux value, which was obtained at the lowest 125 I-A␤40 concentration. NE min is the minimum NE value obtained at the highest 125 I-A␤40 concentration.
Results
The in vivo targeting abilities of molecular probes may be compromised because of rapid elimination from the systemic circulation, competitive inhibition by high circulating A␤ levels in APP,PS1 mice, proteolytic degradation in the brain parenchyma, uptake and degradation by neurons, and efflux from the brain. In this study, we systematically studied and compared the influence of each of the above factors on the amyloid plaque targeting of A␤40 and PUT-A␤40.
I-PUT-A␤40 Plasma Pharmacokinetics
Upon i.v. administration, the 125 I-PUT-A␤40 concentrations in the plasma of WT mice declined rapidly, exhibiting a biexponential disposition with short ␣ and ␤ half-lives [t 1/2(␣) and t 1/2(␤) , respectively] ( Fig. 1; Table 1 ). The C max , t 1/2(␣) , and AUC were significantly lower, whereas the Cl and V ss were significantly higher for 125 I-PUT-A␤40 compared with previously reported values for 125 I-A␤40 (Kandimalla et al., 2005 ). These differences are most likely due to rapid clearance normally observed for cationized proteins (Dellian et al., 2000) or significantly higher metabolism of 125 I-PUT-A␤40 in the peripheral tissues compared with that of 125 I-A␤40.
I-PUT-A␤40 Metabolism in the Peripheral Tissues
To investigate the contribution of peripheral tissue metabolism on the rapid elimination of 125 I-PUT-A␤40 from the systemic circulation, in vitro degradation of 125 I-PUT-A␤40 in the presence of WT mice tissue slices (liver, kidney, and spleen) as well as plasma was studied. Although 125 I-PUT-A␤40 degradation in the WT plasma was slightly higher than the degradation in Dulbecco's modified Eagle's medium, not more than 10% of the initial amount of 125 I-PUT-A␤40 was degraded in 60 min (Fig. 2) . The degradation of 125 I-PUT-A␤40 in the presence of liver slices was similar to that of 125 I-A␤40, with substantial degradation in 60 min. The extent of 125 I-PUT-A␤40 degradation in the kidney and spleen was significantly lower compared with that of 125 I-A␤40 (Fig.  2 ). These results demonstrate that despite rapid clearance from the peripheral circulation compared with 125 I-A␤40, the metabolism of 125 I-PUT-A␤40 in the peripheral organs of elimination was significantly lower than that of 125 I-A␤40.
I-A␤40 Brain Uptake
It has been established in our earlier studies that the PS value, which is a measure of BBB permeability of a protein, of 125 I-PUT-A␤40 is significantly higher than that of 125 I-A␤40 in APP,PS1 mice (Wengenack et al., 2000a) . These transgenic mice develop distinct plaques at the age of 3 months with substantial amyloid burden by 6 months, mostly in the cortex and hippocampus (Wengenack et al., 2000) and carry significantly higher levels of A␤40 (13.9 pmol/ml) in the peripheral circulation compared with WT mice (2.9 pmol/ml) at 6 months (Poduslo et al., 2001) . It was shown that the plaque burden in APP,PS1 animals increases linearly with age (Wengenack et al., 2000b) , and the endogenous A␤40 levels in the peripheral circulation are expected to follow a similar trend. The efficacy of PUT-A␤40 to target plaques in older APP,PS1 animals with high endogenous levels of A␤40 may be compromised if A␤40 competes with PUT-A␤40 for the BBB uptake. Hence, it is important to determine whether A␤40 can competitively inhibit the PUT-A␤40 absorption at the BBB. It was observed that when 1 mg of A␤40 was coadministered with 100 Ci of 125 I-PUT-A␤40, the PS values of 125 I-PUT-A␤40 decreased significantly in various brain regions (Fig. 3) . The V p values, however, did not change significantly because of the coadministration of unlabeled A␤40 (Fig. 3) . To verify that the reduction in the PS values was not due to change in the pharmacokinetics of 125 I-PUT-A␤40 resulting from a possible interaction with unlabeled A␤40 in the syringe before injection, the PS values were determined by first injecting 1 mg of unlabeled A␤40 immediately followed by 100 Ci of 125 I-PUT-A␤40. The PS values (Kandimalla et al., 2005) at the BBB.
Brain Slice Uptake Studies
After permeating the BBB, 125 I-A␤40 or 125 I-PUT-A␤40 must diffuse across the brain parenchyma to reach the plaque sites. The relative diffusivities of 125 I-A␤40 and 125 I-PUT-A␤40 across the brain parenchyma may be directly related to their plaque-targeting capabilities. Hence, the uptake of 125 I-A␤40 and 125 I-PUT-A␤40 into WT mouse brain slices was determined in vitro.
Effect of Time. The uptake of 125 I-A␤40 into WT mouse brain slices was linear till 15 min and reached a plateau from 15 to 60 min (Fig. 4) .
Effect of Donor Concentration. Uptake of 125 I-A␤40 across the WT mouse brain slices was nonlinearly dependent upon the donor concentration (Fig. 5) . Upon fitting a Michaelis-Menten type expression to the data, the K m and V max were estimated to be 18.4 Ci/ml and 2622 nCi/g wet weight, respectively, whereas 24.8 nCi/g wet weight was estimated to be nonspecifically bound to the tissue. (Fig. 6) . Laser confocal micrograph of F-PUT-A␤40 demonstrated numerous dark spots amid intensely fluorescent background in the cortex. These results suggest that F-PUT-A␤40 was not taken up by the cells and remained in the extracellular space of the brain parenchyma (Fig. 6) .
Localization of F-A␤40 and PUT-A␤40 (F-PUT-A␤40) in the Brain
Effects of Metabolic Inhibitors. The uptake of 125 I-A␤40 in the WT brain slices treated with metabolic inhibitors such as ouabain (ATPase inhibitor) or 2,4-DNP (uncoupler of oxidative phosphorylation) was reduced significantly compared with the untreated brain slices (Fig. 7) , suggesting that the brain slice uptake of 125 I-A␤40 is energy-dependent and carrier-mediated. The uptake of 125 I-PUT-A␤40 in the WT brain slices was not significantly affected in the presence of a metabolic inhibitor such as 2,4-DNP (Fig. 7) . Hence, the uptake of 125 I-PUT-A␤40 in the brain slices is more likely by passive diffusion.
I-A␤40 and I-PUT-A␤40 Efflux from Brain Slices
As indicated above and from earlier studies conducted in our lab, A␤40 efflux from WT brain slices could be inhibited by 2,4-DNP, which strongly suggested that it is a carriermediated process (Kandimalla et al., 2005) . In the next experiment, we evaluated the saturability of 125 I-A␤40 efflux process and compared it with that of 125 I-PUT-A␤40 (Fig. 8 ). The initial rates of 125 I-A␤40 efflux from WT brain slices, normalized with the donor concentration, decreased with an increase in log donor concentration. In contrast, the normalized initial rates of 125 I-PUT-A␤40 efflux from WT brain slices did not change appreciably with log donor concentration. These results demonstrated that the efflux of 125 I-A␤40 from WT brain slices is carrier mediated, whereas the efflux of 125 I-PUT-A␤40 is predominantly by passive diffusion.
Biophysical Characterization of A␤40 and PUT-A␤40
CD Spectra. The CD spectra of A␤40 and PUT-A␤40 illustrated in Fig. 9 demonstrate that A␤40 has a random coil structure, whereas PUT-A␤40 assumes a ␤-sheet structure in phosphate-buffered saline, pH 7.2, at 4°C.
Kinetics of Fibril Formation. It is believed that high concentration of soluble A␤ accumulates over time in the brain extracellular space, polymerizes into insoluble fibrils, and eventually forms amyloid plaques. The ease with which a molecule can form fibrils is considered a direct measure of its likelihood to provide a seed for plaque formation. The ideal diagnostic probe would not form fibrils after reaching the brain parenchyma but only bind to pre-existing plaques. We studied the fibril formation of A␤40 and PUT-A␤40 using THT assay (Levine, 1993) . THT binds to the ␤-sheet structure of fibrils and emits fluorescence. The intensity of the fluorescence provides a direct measure of the extent of fibril formation. The intensity of THT fluorescence plotted against time in Fig. 10 describes the kinetics of A␤40 and PUT-A␤40 fibril formation. A␤40 forms fibrils with a lag time of 2 h, whereas PUT-A␤40 forms fibrils readily. Moreover, the extent of fibril formation with PUT-A␤40 was substantially higher than A␤40 reflected in the larger fluorescence intensity. At the end of the experiment, the fibril formation was verified by electron microscopy (data not shown).
Discussion
I-A␤40 and
125 I-PUT-A␤40 have demonstrated a differential ability to target amyloid plaques in APP,PS1 transgenic mice after i.v. injection. As a result, they are used in this study as model compounds to investigate various physiological factors (plasma clearance, BBB permeability, parenchymal diffusion and metabolism, and efflux from the central nervous system) and biophysical factors (effect of charge, ability to form fibrils, and affinity to plaques) that affect plaque targeting.
It is generally believed that lower plasma clearance result- ing in high sustained plasma levels of the probe will enhance its BBB permeability. Our earlier studies demonstrated that 125 I-A␤40 is rapidly eliminated from the systemic circulation as a result of significant renal clearance and hepatic metabolism (Kandimalla et al., 2005) . Despite better plaque-targeting ability, 125 I-PUT-A␤40 is more rapidly cleared from the systemic circulation than 125 I-A␤40 after i.v. administration. Unlike 125 I-A␤40, the rapid clearance of 125 I-PUT-A␤40 did not correlate with its metabolism in the peripheral tissues such as liver, kidney, and spleen. Although the metabolism of 125 I-PUT-A␤40 in the liver slices was only slightly lower compared with 125 I-A␤40, its metabolism in kidney slices was significantly lower than 125 I-A␤40. Because the molecular size of 125 I-PUT-A␤40 or 125 I-A␤40 is small, these molecules can be eliminated by the kidney without the need for initial catabolism in the liver. Moreover, the microvascular permeability of cationized proteins like 125 I-PUT-A␤40 was found to be substantially higher than the native proteins (Dellian et , 2000) , resulting in their increased renal clearance. Although higher microvascular permeability can increase the distribution of 125 I-PUT-A␤40 to brain (Poduslo and Curran, 1996b) , increase in the renal clearance and rapid distribution to peripheral tissues could diminish the net effect. Hence, it is unlikely that the better plaque-targeting ability of 125 I-PUT-A␤40 compared with 125 I-A␤40 is due to favorable plasma pharmacokinetics.
Like the BBB permeability of 125 I-A␤40, which decreased significantly in the presence of unlabeled A␤40 (0.125-2 mg) in a dose-dependent manner (Kandimalla et al., 2005) , the BBB permeability of 125 I-PUT-A␤40 decreased when coadministered with 1 mg of A␤40. Even though the PS value of 125 I-PUT-A␤40 is higher than that of 125 I-A␤40 in WT mice, the PS value of 125 I-PUT-A␤40 coadministered with 1 mg of A␤40 was similar to the PS value of 125 I-A␤40 coadministered with 1 mg of A␤40. These results indicate that the BBB permeability of 125 I-PUT-A␤40 is also saturable. Therefore, endogenous A␤40 levels in the peripheral circulation of AP-P,PS1 animals, which were reported to increase linearly with age, could affect the BBB permeability of 125 I-PUT-A␤40 to a similar extent as 125 I-A␤40. Based on this information, it is likely that a modest 1.5-to 2.0-fold higher PS value of 125 I-PUT-A␤40 compared with 125 I-A␤40 (Wengenack et al., 2000a ) may, at the best, have a limited contribution to the differences in their plaque-targeting abilities.
Our earlier work demonstrated that the accumulation of 125 I-A␤40 in the extracellular space of APP,PS1 mouse brain is primarily influenced by the reduced clearance of A␤40, mediated by metabolism and/or efflux, from the brain parenchyma (Kandimalla et al., 2005) . Mouse brain slices containing cortex and hippocampus were used in this study as in vitro model to investigate the role of parenchymal metabolism and uptake on the differential plaque-targeting ability of 125 I-A␤40 and 125 I-PUT-A␤40. This in vitro model has been used by several researchers to study the metabolism (Newman et al., 1990 ) and diffusion of ions (Newman et al., 1995) and small (Gredell et al., 2004 ) and large molecules (Patlak et al., 1998) in the brain parenchyma. Uptake of 125 I-A␤40 into WT mouse brain slices followed MichaelisMenten kinetics, which suggested that the uptake is saturable. The inhibition of 125 I-A␤40 uptake in WT mouse brain slices by metabolic inhibitors such as 2,4-DNP and ouabain suggested that it is energy-dependent and most likely carrier-mediated. Preferential localization of F-A␤40 in the brain parenchymal cells, most likely neurons, after a short incubation time (5 min) further confirms the presence of carriermediated transport of A␤40.
In contrast, the metabolic inhibitors such as 2,4-DNP did not affect the uptake of 125 I-PUT-A␤40 significantly, thereby suggesting that the uptake of 125 I-PUT-A␤40 in WT mouse brain slices is most likely by passive diffusion. Localization of F-PUT-A␤40 in the extracellular space of the brain parenchyma but not in the cells provides further evidence that there is no receptor-mediated uptake of PUT-A␤40. The cellular uptake of A␤40 in the brain parenchyma makes it unavailable for targeting the plaques located in the extracellular space. In contrast, PUT-A␤40 is not taken up by the cells, remains in the extracellular space, and is available for binding to plaques, a desirable feature for imaging amyloid plaques.
In vitro fibril binding studies demonstrated that both 125 I-A␤40 and 125 I-PUT-A␤40 bind to A␤40 fibrils with similar affinity (data not shown). However, the differences in the extracellular concentrations of the probe can alter plaque binding significantly. The extracellular concentration of 125 I-A␤40 is not only reduced because of cellular uptake but also by the efflux and parenchymal metabolism. The degradation of 125 I-PUT-A␤40 in the WT mouse brain slices was significantly lower than the previously reported degradation of 125 I-A␤40 (Kandimalla et al., 2005) . The efflux of 125 I-A␤40 across WT mouse brain slices was found to be saturable and inhibited by 2,4-DNP (Kandimalla et al., 2005) , thereby suggesting that it is energy-dependent and carrier-mediated. The efflux of 125 I-PUT-A␤40, on the other hand, was much slower compared with that of 125 I-A␤40 and was not dependent upon the donor concentration, suggesting that it occurs via passive diffusion.
Despite its success in providing contrast enhancement of plaques after i.v. injection during MRI of APP,PS1 mouse brains ex vivo, the utility of PUT-Gd-A␤40 for diagnostic use in animal models and patients is limited because carbodiimide-mediated modification of A␤40 with putrescine is associated with problems inherent with the protein itself, such as crosslinking, aggregate and/or fibril formation, and insolubility. In addition, PUT-A␤40 forms fibrils more readily than A␤40. The ease with which a molecule can form fibrils is considered as a direct measure of its likelihood to provide a seed for plaque formation.
Hence, a new probe, Gd[N-4ab/Q-4ab]A␤30, was produced as a putative MRI contrast enhancement agent by first synthesizing a glutamyl-4-aminobutane or asparagyl-4-aminobutane, which were then incorporated into the synthesis of the protein using standard solid-phase methods (Poduslo et al., 2004) . The complete chemical synthesis of this probe eliminates peptide crosslinking, aggregate and fibril formation, and insolubility that affected the carbodiimide-mediated modification of A␤40 with putrescine. Apart from having the chemical purity, this probe is devoid of the neurotoxic domain found in A␤40 and is not amyloidogenic like A␤40. In addition, Gd[N-4ab/Q-4ab]A␤30 has good BBB permeability and labels neuritic plaques in vitro with affinity comparable with PUT-A␤40. However, attempts to image amyloid plaques in APP,PS1 animals in vivo using this agent yielded only modest results. Studies are being conducted to enhance the in vivo efficacy of this probe through appropriate structural modifications to influence various physiological factors, parenchymal metabolism and neuronal uptake, that were determined in the present study to adversely affect the plaque-targeting ability.
In summary, these studies demonstrated that both 125 I-A␤40 and 125 I-PUT-A␤40 are rapidly eliminated from the systemic circulation after i.v. administration in WT animals. However, the peripheral pharmacokinetics of the probes did not significantly influence their plaque-targeting capabilities. The higher concentration of endogenous A␤40 in the peripheral circulation decreases the permeability of both compounds at the BBB. The metabolism of 125 I-PUT-A␤40 is substantially lower in the brain slices compared with that of 125 I-A␤40. This indicates that 125 I-PUT-A␤40 is metabolically stable and may remain intact in the brain parenchyma with higher concentrations being available for plaque targeting than 125 I-A␤40. In addition, the rate of 125 I-PUT-A␤40 efflux in WT brain slices was substantially lower compared with that of 125 I-A␤40. Hence, 125 I-PUT-A␤40 tends to remain in brain parenchyma longer than 125 I-A␤40. This study also demonstrates that the fluorescein-labeled A␤40, but not 125 I-PUT-A␤40, is taken up by cells, which makes the former unavailable for targeting the plaques located in the extracellular space. By comparing the distribution and metabolism of 125 I-A␤40 and 125 I-PUT-A␤40 after i.v. administration, it can be concluded that the inadequate targeting of 125 I-A␤40 to amyloid plaques despite its carrier-mediated uptake at the BBB could be due to cellular uptake, metabolism, and efflux of A␤40 in the brain parenchyma. The knowledge gained from these studies will be very useful in the development of new A␤ derivatives with improved BBB permeability and plaque targeting.
